4.5 Letter

Soluble B7-H1: Differences in production between dendritic cells and T cells

Journal

IMMUNOLOGY LETTERS
Volume 142, Issue 1-2, Pages 78-82

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.imlet.2011.11.001

Keywords

B7-H1; Soluble; T cell; Dendritic cell; Coregulatory; Tumor cell

Categories

Funding

  1. NCI NIH HHS [R01 CA134345] Funding Source: Medline

Ask authors/readers for more resources

Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H coregulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules. (C) 2011 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available